226 related articles for article (PubMed ID: 33112294)
21. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
23. Nausea, vomiting and thyroid function before and after induced abortion in normal pregnancy.
Appierto U; Subrizi DA; Minozzi M; Unfer V
Clin Exp Obstet Gynecol; 1996; 23(1):18-20. PubMed ID: 8653928
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues.
Staub JJ; Althaus BU; Engler H; Ryff AS; Trabucco P; Marquardt K; Burckhardt D; Girard J; Weintraub BD
Am J Med; 1992 Jun; 92(6):631-42. PubMed ID: 1605145
[TBL] [Abstract][Full Text] [Related]
25. Medical monitoring in patients with bipolar disorder: clinical recommendations.
Friedman ES
J Clin Psychiatry; 2009 Aug; 70(8):e27. PubMed ID: 19758516
[TBL] [Abstract][Full Text] [Related]
26. Metabolic adverse events of multitarget kinase inhibitors: a systematic review.
Acitelli E; Maiorca C; Grani G; Maranghi M
Endocrine; 2023 Jul; 81(1):16-29. PubMed ID: 37067769
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus.
Celani MF; Bonati ME; Stucci N
Diabetes Res; 1994; 27(1):15-25. PubMed ID: 7648793
[TBL] [Abstract][Full Text] [Related]
28. The impacts of organochlorines and other persistent pollutants on thyroid and metabolic health.
Langer P
Front Neuroendocrinol; 2010 Oct; 31(4):497-518. PubMed ID: 20797403
[TBL] [Abstract][Full Text] [Related]
29. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.
Yuan A; Kurtz SL; Barysauskas CM; Pilotte AP; Wagner AJ; Treister NS
Oral Oncol; 2015 Nov; 51(11):1026-1033. PubMed ID: 26403941
[TBL] [Abstract][Full Text] [Related]
30. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
31. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
32. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.
Villadolid J; Ersek JL; Fong MK; Sirianno L; Story ES
Transl Lung Cancer Res; 2015 Oct; 4(5):576-83. PubMed ID: 26629426
[TBL] [Abstract][Full Text] [Related]
33. Metabolic Complications in Adrenal Insufficiency.
Ueland GA; Husebye ES
Front Horm Res; 2018; 49():104-113. PubMed ID: 29894991
[TBL] [Abstract][Full Text] [Related]
34. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Li J; Gu J
Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
[TBL] [Abstract][Full Text] [Related]
35. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
36. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Tinsley SM
J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830
[TBL] [Abstract][Full Text] [Related]
37. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
Atallah E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S105-12. PubMed ID: 17382019
[TBL] [Abstract][Full Text] [Related]
38. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
39. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
[TBL] [Abstract][Full Text] [Related]
40. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Toubert ME; Vercellino L; Faugeron I; Lussato D; Hindie E; Bousquet G
Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
